Teva's Opioid Vantrela: Conflicting Data On Oral Abuse Deterrence
This article was originally published in The Pink Sheet Daily
Human abuse liking study, in vitro data paint different pictures of potential for hydrocodone extended-release product to deter oral abuse, FDA says ahead of advisory committee review; agency finds support for abuse-deterrent claims for intranasal, intravenous use.
You may also be interested in...
Opioid REMS Prescriber Education Should Be Mandatory, FDA Panel Says
This time, the agency may be ready to agree with its advisory committee.
Califf Nomination Suffers 'Pile On': What Can FDA Do To Break Logjam?
Sen. Alexander and others remain optimistic as several holds and a filibuster threat emerge.
At Tofersen Panel Review, US FDA Shined A Light On Internal Differences Of Opinion
Agency’s presentations on Biogen/Ionis’ ALS drug included differing viewpoints from the statistical and clinical pharmacology teams; the transparency and emphasis on a multidisciplinary review approach may reflect lessons learned from missteps at the Aduhelm panel review in 2020.